ClinConnect ClinConnect Logo
Search / Trial NCT01126203

Randomized Prospective Study of Selective Laser Trabeculoplasty (SLT) Versus Argon Trabeculoplasty (ALT) in Patients With Pseudoexfoliation Glaucoma and Ocular Hypertension

Launched by UNIVERSITY OF CALGARY · May 18, 2010

Trial Information

Current as of June 14, 2025

Completed

Keywords

Pseudoexfoliation Glaucoma Ocular Hypertension Slt Selective Laser Trabeculoplasy (Slt) Argon Laser Trabeculoplasty (Alt)

ClinConnect Summary

This study derives from a clinical observation that laser treated eyed with PXF glaucoma may have a similar long-term response rates when either ALT or SLT is performed. Some authors have considered that there is a risk of IOP elevation in the immediate post laser period with ALT or SLT as a complication to be related to denser angle pigmentation (20,48). (46) No long-term analysis comparing response rates of both laser treatments in these types of patients has been done.

Primary objective is to determine which laser therapy has more IOP lowering effect as primary or adjunctive treatment i...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Only patients with clinical evidence of unilateral or bilateral open angle pseudoexfoliation ocular hypertension (IOP \> 22mmHg) or glaucoma (Evidence on Humphrey 30-2 or Goldmann of nerve fiber layer damage) with uncontrolled IOP, over 18 years of age, and are willing to participate in the study will be included. If increased IOP is bilateral then the worst eye will be treated.
  • Exclusion Criteria:
  • Patients will be excluded if they have evidence of any glaucoma other than pseudoexfoliative open angle, if the trabecular meshwork cannot be seen in 360 degrees, if they had previous laser therapy ALT or SLT, if they have advanced visual field defect (split fixation or a scotoma within 10 degrees fixation), taking any systemic or topical steroids, have had any previous ocular surgery (glaucoma or cataract extraction included) or laser within the previous six months, if they are monocular patients, if they have any corneal disease precluding the angle evaluation and treatment, or if they had ocular trauma.

About University Of Calgary

The University of Calgary is a leading research institution dedicated to advancing health and science through innovative clinical trials. With a strong emphasis on multidisciplinary collaboration, the university's clinical research initiatives aim to address pressing health challenges and improve patient outcomes. The institution fosters a robust environment for academic inquiry, leveraging state-of-the-art facilities and a diverse network of experts in various fields. Committed to ethical research practices and community engagement, the University of Calgary strives to translate scientific discoveries into tangible benefits for society.

Locations

Ottawa, Ontario, Canada

Montreal, Quebec, Canada

Calgary, Alberta, Canada

London, Ontario, Canada

Toronto, Ontario, Canada

Patients applied

0 patients applied

Trial Officials

Andrew C Crichton

Principal Investigator

University of Calgary

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials